FDA Expands Venclexta Approval for Previously Untreated CLL and SLLThe U.S. Food and Drug Administration (FDA) has recently expanded the approval for Venclexta® (venetoclax). Venclexta is now approved for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia... By Pamela Munnelly1 min readBookmark for later Reactions 0 reactions Comments1 comments
Take The Clinical Trial Patient Voice Survey (Now Closed)Have you participated in a clinical trial? Are you interested in participating in future clinical trials? We want to hear more about your experience! Blood-Cancer.com/Health Union is teaming up with... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments1 comments
FDA Expands Approval of Tibsovo for Treatment of AML with IDH1 MutationThe U.S. Food and Drug Administration (FDA) has expanded the approval of Tibsovo® (ivosidenib), a targeted therapy, for newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in people... By Pamela Munnelly1 min readBookmark for later Reactions 0 reactions Comments0 comments
Introducing Our New Accessibility FeatureYou may have noticed that we added a new accessibility feature to our website. This feature will allow community members to change the size, color, or contrast of the text... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments1 comments
FDA Warns of Risks Identified in a Clinical Trial for Multiple MyelomaThe U.S. Food & Drug Administration (FDA) has issued a partial clinical hold and safety warning regarding the investigational use of Venclexta® (venetoclax) for multiple myeloma. This safety warning does... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments0 comments
Death Rates from Cancer Continue to Fall in the USDeath rates from common cancers have continued a 25-year decline throughout the United States. From 1991-2016, the overall death rate from cancer declined 27%, resulting in an estimated 2.6 million... By Editorial Team4 min readBookmark for later Reactions 0 reactions Comments2 comments
Elzonris Approved for BPDCN and Sprycel Approval ExpandedThe FDA has approved ElzonrisTM (tagraxofusp-erzs), a targeted therapy, for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and children over age 2. This is the first... By Pamela Munnelly1 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Asparlas for ALL in Children and Young AdultsThe U.S. Food and Drug Administration (FDA) announced approval of AsparlasTM for acute lymphoblastic leukemia (ALL) on December 20, 2018.1,2 Asparlas is a longer-acting calaspargase pegol-mknl, an asparagine specific enzyme... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments0 comments
Research Shows Cancer Likely to Become More Deadly than Heart DiseaseHeart disease is the leading cause of death in Americans, but new research shows that cancer is likely to surpass heart disease as the number one killer in 2020, especially... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves First Biosimilar to Rituxan & New Drug for AMLOn November 28, 2018, the U.S. Food and Drug Administration (FDA) approved two new products that affect the blood cancer community: Truxima® (rituximab-abbs) and Xospata® (gilteritinib). Truxima is approved to... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves 2 New Treatments for AML in Older Adults & Patients with ComorbiditiesThe U.S. Food and Drug Administration (FDA) recently approved two new treatment options for certain people with acute myeloid leukemia (AML): Daurismo™ (glasdegib) and Venclexta® (venetoclax) in combination with other... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments0 comments
First FDA Approval for Newly Diagnosed Types of Peripheral T-Cell LymphomaThe U.S. Food and Drug Administration (FDA) has approved Adcetris® (brentuximab vedotin) in combination with chemotherapy for the treatment of some peripheral T-cell lymphomas (PTCL). The approval was made through... By Pamela Munnelly1 min readBookmark for later Reactions 0 reactions Comments3 comments
FDA Approves New Immunotherapy Combination for Multiple MyelomaThe U.S. Food and Drug Administration (FDA) recently approved Empliciti® (elotuzumab) as part of a combination treatment to treat certain people with relapsed or refractory multiple myeloma (MM). Empliciti can... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments0 comments
Blood Cancer in the News: Paul Allen, Roman Reigns, Scott WilsonOver the last few weeks, blood cancer has been in the news due to the passing of celebrities Paul Allen and Scott Wilson, as well as surprise announcement by wrestler... By Pamela Munnelly1 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves First Next-Generation Sequencing Test for Minimal Residual Disease of ALL and Multiple MyelomaOn September 28, 2018, the U.S. Food and Drug Administration (FDA) approved the first next-generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments1 comments
FDA Approves Copiktra for CLL/SLL and Follicular LymphomaOn September 24, 2018, the U.S. Food and Drug Administration (FDA) approved a new treatment for certain types of blood cancer: Copiktra (duvelisib). Manufactured by Verastem, Copiktra is approved to... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments0 comments
Used or Considered CAR T-Cell Therapy? We Want to Hear From You!Have you had CAR T-cell therapy or considered it? If so, we’d like to hear from you. Please enter your email information below and we will contact you for a... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Lumoxiti for Hairy Cell LeukemiaOn September 13, 2018, the U.S. Food and Drug Administration (FDA) approved a new treatment option for adults with hairy cell leukemia (HCL) who have tried at least two prior... By Emily Downward2 min readBookmark for later Reactions 0 reactions Comments0 comments
How's Your Relationship with Your Doctor? Take our Survey!Do you feel heard by your doctor? Do your questions get answered? We want to hear from you! We’re conducting a survey to learn more about your relationship with your... By Editorial Team1 min readBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves First Non-Chemotherapy Combination for Waldenstrom MacroglobulinemiaThe U.S. Food and Drug Administration (FDA) has approved the combination of Imbruvica® (ibrutinib) with Rituxan® (rituximab) for the treatment of Waldenstrom macroglobulinemia in adults. This is the first non-chemotherapy... By Pamela Munnelly1 min readBookmark for later Reactions 0 reactions Comments0 comments
